<?xml version="1.0"?>
<oembed><version>1.0</version><provider_name>Brakke&#x54A8;&#x8BE2;&#x7F51;&#x7AD9;</provider_name><provider_url>https://brakkeconsulting.com/zh</provider_url><title>News from Brakke Consulting</title><type>rich</type><width>600</width><height>338</height><html>&lt;blockquote class="wp-embedded-content" data-secret="xoWKpgku6g"&gt;&lt;a href="https://brakkeconsulting.com/zh/brakke-viewpoint-october-25-2024/"&gt;&#x5E03;&#x62C9;&#x514B;&#x89C2;&#x70B9; 2024 &#x5E74; 10 &#x6708; 25 &#x65E5;&lt;/a&gt;&lt;/blockquote&gt;&lt;iframe sandbox="allow-scripts" security="restricted" src="https://brakkeconsulting.com/zh/brakke-viewpoint-october-25-2024/embed/#?secret=xoWKpgku6g" width="600" height="338" title="&#x300A;&#x5E03;&#x62C9;&#x514B;&#x89C2;&#x70B9;2024&#x5E74;10&#x6708;25&#x65E5;&#x300B;&#x2014;&#x5E03;&#x62C9;&#x514B;&#x54A8;&#x8BE2;&#x7F51;&#x7AD9;" data-secret="xoWKpgku6g" frameborder="0" marginwidth="0" marginheight="0" scrolling="no" class="wp-embedded-content"&gt;&lt;/iframe&gt;&lt;script type="text/javascript"&gt;
/* &lt;![CDATA[ */
/*! This file is auto-generated */
!function(d,l){"use strict";l.querySelector&amp;&amp;d.addEventListener&amp;&amp;"undefined"!=typeof URL&amp;&amp;(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&amp;&amp;!/[^a-zA-Z0-9]/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret="'+t.secret+'"]'),o=l.querySelectorAll('blockquote[data-secret="'+t.secret+'"]'),c=new RegExp("^https?:$","i"),i=0;i&lt;o.length;i++)o[i].style.display="none";for(i=0;i&lt;a.length;i++)s=a[i],e.source===s.contentWindow&amp;&amp;(s.removeAttribute("style"),"height"===t.message?(1e3&lt;(r=parseInt(t.value,10))?r=1e3:~~r&lt;200&amp;&amp;(r=200),s.height=r):"link"===t.message&amp;&amp;(r=new URL(s.getAttribute("src")),n=new URL(t.value),c.test(n.protocol))&amp;&amp;n.host===r.host&amp;&amp;l.activeElement===s&amp;&amp;(d.top.location.href=t.value))}},d.addEventListener("message",d.wp.receiveEmbedMessage,!1),l.addEventListener("DOMContentLoaded",function(){for(var e,t,s=l.querySelectorAll("iframe.wp-embedded-content"),r=0;r&lt;s.length;r++)(t=(e=s[r]).getAttribute("data-secret"))||(t=Math.random().toString(36).substring(2,12),e.src+="#?secret="+t,e.setAttribute("data-secret",t)),e.contentWindow.postMessage({message:"ready",secret:t},"*")},!1)))}(window,document);
//# sourceURL=https://brakkeconsulting.com/wp-includes/js/wp-embed.min.js
/* ]]&gt; */
&lt;/script&gt;</html><description>Finally, election season is upon us.&#xA0; But for finance nerds like myself, earning season is here as well with 3Q24 corporate earnings reports beginning in early November.&#xA0; It will be very interesting to see not only what the companies have to say about third quarter results but what signals they send for the rest of 2024 and 2025. I recently saw some data from Vetsource that indicates that through the end of September, foot traffic through the vet clinic is down by -1.8% vs. 2023.&#xA0; However, at the clinic level, revenues have increased by +3.1% indicating a continuation of solid price contribution. In the companion animal space, innovation is the most critical driver of growth.&#xA0; Elanco for example, is about to enter a wave of new product introductions in some of the largest market segments including flea/tick/heartworm (F/T/HW) and dermatology.&#xA0; BI recently launched NexGard Plus in the US.&#xA0; Zoetis&#x2019; growth in F/T/HW, dermatology and osteoarthritis is unmatched and Merck has received approval in Europe/Australia on the next wave of F/T innovation with a long-acting injectable product.&#xA0; All of these therapies come with higher price tags. Will this innovation be enough to continue to drive growth?&#xA0; Will these products, especially the injectables and monoclonal antibody products, drive pet owners back to the clinic or will the increased prices finally create aView Full Post;</description></oembed>
